Breaking News, Collaborations & Alliances

Ananda Scientific, Benta SAS Sign MOU to Advance Treatments for PTSD

Will explore a potential collaboration focused on accelerating the development and future availability of a new treatment for Post-Traumatic Stress Disorder.

Author Image

By: Charlie Sternberg

Associate Editor

Bernard Tannoury, President of Benta SAS, and Sohail Zaidi, CEO of Ananda Scientific Inc., signing the MOU.

Ananda Scientific Inc., a clinical-stage drug development company, and Benta SAS have signed a Memorandum of Understanding (MOU) which expresses the parties’ intent to explore a potential collaboration focused on accelerating the development and future availability of a new treatment for Post-Traumatic Stress Disorder (PTSD) in Europe and the Middle East/North Africa (MENA) region. PTSD affects millions of people worldwide, yet there has been no new approved drug for PTSD in over two decades ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters